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ABSTRACT.
Purpose: The International Neonatal Consortium recently published a proposed
retinopathy of prematurity (ROP) activity scale intended for use in clinical trials
after validation. The aim of this study was to validate the ROP activity scale
(ROP-ActS) in a ROP screened cohort with protocol based collected data by
evaluating the ability of the ROP-Act scores to predict ROP treatment. In
addition, we aimed to evaluate the scale’s sensitivity characteristic of disease
severity by studying association with gestational age (GA) in comparison with
conventionally used ROP stage and zone.
Methods: A cohort of 535 preterm infants with 3324 ROP examinations with an
end-point of ROP treatment or end of screening in Gothenburg, Sweden, was
included. Median GA was 28.1 weeks, 47.5% were girls, and 74 (13.8%) infants
were treated for ROP. The validation was performed by estimating probabilities
for ROP treatment, and by applying logistic and linear regression.
Results: The original ROP-ActS was overall well-ordered with respect to ability
to predict ROP treatment but could be improved by re-ordering score 3 (zone II
stage 1) and 5 (zone III stage 3) based on our clinical cohort data. The modified
ROP-ActS was superior to ROP stage and zone in the prediction analysis of
ROP treatment. Modified ROP-ActS was more strongly related to GA than
currently used ROP stage, but not zone.
Conclusion: In the studied cohort, the modified ROP-ActS could better predict
ROP treatment compared to ROP stage and zone. Retinopathy of Prematurity
Activity Scale (ROP-ActS) had a superior sensitivity characteristic studied
through association to GA than conventionally used ROP stage.
Key words: retinopathy of prematurity – ROP activity scale – ROP-ActS – ROP stage – ROP
zone
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Introduction
The International Neonatal Consor-
tium (INC) is focused on developing
objective descriptors of all stages of
retinopathy of prematurity (ROP) to
discriminate effects of prevention and
treatment. Current studies apply the
parameters stage, location (zone I-III),
extent of proliferative disease and pre-
plus/plus disease of the International
Classification of Retinopathy of Prema-
turity (ICROP) for classification
(ICROP, 2005). The decision to treat
severe ROP is based on a defined com-
bination of these variables (type 1 ROP
[treatment-requiring] and type 2 ROP
[not requiring treatment]). Clinical stud-
ies reporting ROP severity most com-
monly use type or stage only (Stahl et al.,
2018; Stahl et al., 2019; Tu et al., 2019).
Regulatory authorities asked mem-
bers of the INC to develop an ROP
activity scale (ROP-ActS) that would
improve sensitivity of disease severity
(Smith et al., 2019). The more sensitive
the studied measure is, the better the
ability to discriminate between treat-
ments, and the higher the statistical
power in clinical trials. The developed
ROP-ActS is based on a scale which
included all theoretically possible com-
binations of the three currently used
ICROP determinants defining ROP
severity (zone, stage and presence of
plus disease) (ICROP, 2005). These 23
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combinations (range 0 [no ROP] to 22
[stage 5 ROP]) were originally ranked
by ‘severity’ based on the clinical
judgement of nine ROP experts (Smith
et al., 2019). Validation studies on a
cohort with short-term, long-term and
safety outcomes based on well docu-
mented, prospectively or retrospec-
tively collected data were considered
necessary in the original publication of
the scale (Smith et al., 2019). Until
now, the ROP-ActS has not been
evaluated on a clinical cohort.
The primary aim of the current study
was to validate the ROP-ActS using
data from all prematurely born infants
that were screened for ROP during
2013–2018 at Sahlgrenska University
Hospital in Gothenburg, Sweden. Sec-
ondly, it was to study the order of
severity of the various scale components
to predict ROP treatment and tomodify
the scale if needed. Additionally, we
wished to evaluate if the initial ROP-
ActS scale could predict ROP treatment
and its association to GA compared to
currently used ROP stages and zones.
Materials and methods
The study was approved by the ethical
review board in Sweden Dnr 2019-
02321.
Study procedures
Gestational age (GA)was estimated from
the postmenstrual week 18 fetal ultra-
sound. For infants born at
GA ≥ 24 weeks, a standard deviation
score (SDS) showing difference from
expected reference birthweight (BWSDS)
was calculated,basedonGAatbirth,BW
and sex (Niklasson & Albertsson-Wik-
land, 2008). All data were reported at the
study site according to a standardized
ROPprotocol.Five experiencedophthal-
mologists performed the ROP examina-
tions.Retinopathyof Prematurity (ROP)
stage, zone and status of plus diseasewere
defined according to the International
Classification of Retinopathy of Prema-
turity (ICROP, 2005). Those three vari-
ables were also used for the definition of
theROP-ActS (Table S1). Theworst case
of left and right eye was analysed.
Study outcome
Retinopathyof prematurity (ROP) treat-
ment, following the Early Treatment of
Retinopathy of Prematurity (ETROP)
criteria (ETROP, 2003), is the study
outcome. For infants treated for ROP,
data up to the date of the first treatment
were used. For all other infants, data
from all ROP screening examinations
were included in the analyses.
Study population used for validation of the
ROP Activity Scale (ROP-ActS)
Informed consent from the parents/
guardians was obtained to collect ROP
screening data for the Swedish
National Registry for Retinopathy of
Prematurity (SWEDROP) to be used
for clinical care improvement.
All 535 infants screened for ROP
between 1 January 2013 and 31 Decem-
ber 2018 at the paediatric ophthalmol-
ogy department at the Queen Silvia
Children’s Hospital in Gothenburg,
Sweden, were included in this study.
There were 3898 screening examina-
tions; 419 (10.7%) post-treatment
examinations were excluded for infants
treated for ROP, leaving 3479 (89.3%)
available for consideration. Of those,
3324 (95.5%) had the reported data
required for evaluation of the ROP-
ActS. Reasons for missing data were
retrieved from the medical records.
Seventy-one (2.0%) examinations,
occurring most often at the start of
the screening, were excluded because
examiners were unable to assess very
immature retinas and/or for insufficient
dilatation of the pupil. Additionally, 10
(0.3%) visits were excluded because of
difficult or incomplete examinations
(n = 4), unstable very sick infant
(n = 4), regression reported without
specified detailed data (n = 1) and
patient examined at another site
(n = 1). The ROP-ActS was not evalu-
ated for 74 (2.1%) visits that occurred
on the day of the first ROP treatment.
Therefore, data from those 74 exami-
nations were used to define the status
and timing of ROP treatment.
Statistical analysis
Categorical variables were described by
number and percentage, and continu-
ous variables by mean, standard devi-
ation (SD), median, minimum and
maximum.
The logical partial order restrictions
based on increasing severity: ROP stages
1–3; zone III–I; no plus to plus disease,
were checked and observed fulfilled for
the ROP-ActS (Appendix S1). The order
of the scores in the activity scale accord-
ing to the severity of the disease was
evaluated by calculating the percentage
with 95% confidence intervals (CI) of
infants with incident ROP treatment
among infants ever experiencing a cer-
tain score. The percentages were numer-
ically compared and graphically
presented in bar charts. The modified
ROP-ActS was suggested based on the
outcome from these analyses of the
scale’s correspondence to the severity of
the disease.
The ability of the most severe value
before 10 weeks of postnatal age of the
original, modifiedROP-ActS, ROP stage
and zone to predict ROP treatment (end-
point) was analysed using univariable
and multivariable logistic regression,
with risks studied linearly increasing by
one step increase. The multivariable
analysis was performed to study whether
modified ROP-ActS, ROP stage and
zone would remain significant predictors
when adjusted for each other, and when
adjusted for GA, weight and sex. Odds
ratio (OR) with 95% CI and area under
receiver operating characteristic (ROC)
curve were presented.
In order to examine the preference of
selecting either of the original, modified
ROP-ActS, ROP stage or zone as
exposure variable in a study, the asso-
ciation between the most severe values
of the four variables before week 10 of
postnatal age and gestational age was
analysed using univariable and multi-
variable linear regression. The associa-
tions were studied among all infants and
among those experiencing any ROP up
to 10 weeks of postnatal age, studying
linear effects between the four indepen-
dent variables and GA. This exercise
was performed in order to evaluate
whether modified ROP-ActS would be
a more sensitive variable regarding
severity of the disease, and therefore
stronger correlated to GA than ROP
stage and zone. Beta estimates with
95% CI, and R2 were presented.
All tests were two-tailed and con-
ducted at 0.05 significance level. All
analyses were performed using SAS
software version 9.4 (SAS Institute
Inc., Cary, NC, USA).
Results
Study population and examinations
Table 1 presents descriptive data for
the overall study population and for
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infants with and without ROP treat-
ment. Among 535 infants included, 254
(47.5%) were girls, mean birthweight
was 1068 (SD 358) grams and median
GA 28.1 (range 22.4–34.4) weeks.
Mean BWSDS was 1.16 (SD 1.53)
among infants born with a GA
≥24 weeks. Mean number of screening
examinations with available ROP-ActS
score data was higher for treated than
for non-treated infants (mean 7.7
[range 2–24] versus mean 6.0 [range
1–30], respectively).
Observed ROP stage, plus disease, zone
and ROP Activity Scale (ROP-ActS)
In this study population, 74 (13.8%)
infants were treated for ROP at least
once (24 born at GA 22–23 weeks
[70.6% of that group], 31 born at GA
24–25 weeks [36.0% of that group] and
19 born at GA 26–27 weeks [14.4% of
that group]); no ROP treatment was
required for any infant born with GA
≥28 weeks. Maximum ROP stage
observed was stage 3 in 107 (20.0%)
infants, stage 2 in 89 (16.6%), stage 1 in
42 (7.9%), leaving 297 (55.5%)
screened infants with no diagnosed
ROP. Among infants with diagnosed
ROP, the most central zone was zone I
in 2 infants only, zone II in 166
(69.7%) and zone III in 70 (29.4%).
60 (25.2%) were diagnosed with plus
disease, 1 with stage 2 and 59 with
stage 3 ROP, Table 1.
For the majority of infants (466
[87.1%]), the first ROP examination
score was 0 (no ROP); 9 (1.7%) had
score 1 (zone III stage 1); 8 (1.5%) had
score 2 (zone III stage 2); 27 (5.0%)
had score 3 (zone II stage 1); 23 (4.3%)
had score 7 (zone II stage 2) observed
at first screening. At first examination,
one infant had score 5 (zone III stage 3)
and one infant had score 8 (zone II
stage 3). The following scores were not
observed in this cohort (and may in
part be physiologically unlikely to
occur): scores 4 (zone III stage 1+), 6
(zone III stage 2+), 10 (zone I stage 1),
11 (zone II stage 1+), 15 (zone I stage
1+), 17 (zone I stage 2+) and 18 (zone I
stage 3+). Other scores that are clini-
cally highly relevant but were also not
seen in this cohort were scores 19–22
(AP-ROP, stage 4a, 4b and 5).
Distribution of longitudinal values
for ROP-ActS and ROP stages and
zones for different gestational weeks is
presented in Figs S1, S2 and S3.
Severity order of the ROP Activity Scale
(ROP-ActS) tested against ROP
treatment
The ROP-ActS fulfilled the logical
partial order restrictions based on
increasing severity of ROP stage, zone
and plus disease (Appendix S1). The
proportions of infants with ROP
treatment among those with each
ROP-ActS score are presented in
Fig. 1 (for ROP-ActS scores 1–18).
The largest relative numerical increase
in the incidence of ROP treatment
between two adjacent ROP-ActS
scores was seen for score 3 (zone II
stage 1) versus score 2 (zone III stage
2), 32.6% (95% CI 23.2%–43.2%)
versus 4.3% (95% CI 1.2%–10.8%),
respectively. Numerical decrease in the
incidence of ROP treatment for an
increased ROP-ActS score was
observed for score 5 (zone III stage
3) versus score 3 (zone II stage 1),
13.6% (95% CI 2.9%–34.9%) versus
32.6% (95% CI 23.2%–43.2%),
respectively. For all other adjacent
comparisons, where data were avail-
able, equal or numerically higher inci-
dences were found for higher scores.
The modified ROP Activity Scale (ROP-
ActS)
Based on the results from the analyses
of correspondence to the severity of the
studied outcome, scores 3 and 5 were
switched with each other, resulting in
the modified ROP-ActS score 3 repre-
senting zone III stage 3 and score 5
representing zone II stage 1. All other
ROP-ActS scores in the modified ver-
sion were left unchanged, Fig. 1 and
Table S1.
Prediction ability of the modified ROP
Activity Scale (ROP-ActS) versus ROP
stage and zone
All four variables, maximum value of
the original and modified ROP-ActS,
as well as most severe ROP stage and
zone, up to postnatal week 10, were
significant predictors for ROP treat-
ment. The observed areas under the
ROC curves were for the modified
ROP-ActS scale 0.82 (95% CI 0.76–
0.87), for the original ROP-ActS 0.81
(95% CI 0.76–0.87), followed by ROP






ROP (n = 461)
Treated for
ROP (n = 74)
Sex
Boys 281 (52.5%) 239 (51.8%) 42 (56.8%)
Girls 254 (47.5%) 222 (48.2%) 32 (43.2%)
Birthweight (g) 1068 (358) 1129 (344) 689 (150)
1020 (440; 2445) 1113 (450; 2445) 678 (440; 1005)
n = 534 n = 460 n = 74
Birthweight SDS
(for gestational age ≥ 24
weeks)
1.16 (1.53) 1.19 (1.57) 0.842 (1.043)
0.86 (8.42; 2.74) 0.87 (8.42;
2.74)
0.724 (3.665; 0.978)
n = 500 n = 450 n = 50
Gestational age
at birth (weeks)
27.8 (2.4) 28.3 (2.1) 24.6 (1.3)
28.1 (22.4; 34.4) 28.7 (22.6; 34.4) 24.4 (22.4; 27.9)
Maximum ROP stage
No ROP 297 (55.5%) 297 (64.4%) 0 (0.0%)
ROP stage 1 42 (7.9%) 42 (9.1%) 0 (0.0%)
ROP stage 2 89 (16.6%) 87 (18.9%) 2 (2.7%)
ROP stage 3 107 (20.0%) 35 (7.6%) 72 (97.3%)
Plus disease (among infants
with diagnosed ROP)
60 (25.2%) 60 (81.1%)
Worst zone (among infants with diagnosed ROP)
Zone I 2 (0.8%) 0 (0.0%) 2 (2.7%)
Zone II 166 (69.7%) 96 (58.5%) 70 (94.6%)
Zone III 70 (29.4%) 68 (41.5%) 2 (2.7%)
For categorical variables, n (%) are presented. For continuous variables, Mean (SD)/Median
(Min; Max)/n = are presented. N is presented for variables having at least one missing value.
ROP = retinopathy of prematurity, SDS = standard deviation score.
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zone 0.81 (95% CI 0.76–0.86) and ROP
stage 0.79 (95% CI 0.73–0.84), Table 2.
The same conclusions were drawn after
adjustment for GA, birthweight and
sex. The modified ROP-ActS had sig-
nificantly superior predictive ability
compared to stage and zone studied
in separate multivariable logistic
regression models.
Association between GA and modified
ROP Activity Scale (ROP-ActS)
compared to ROP stage and zone
Maximum value of the original and
modified ROP-ActS, and most severe
ROP stage and zone, up to postnatal
week 10, were all significantly associ-
ated to GA, analysed on all infants.
The highest R2 of 0.26 was estimated
for the modified ROP-ActS, followed
by ROP zone 0.25, original ROP-ActS
0.23 and ROP stage 0.17 (Table 3).
There was no significant correlation
between ROP stage and GA when
analysed excluding infants with no
ROP. Modified ROP-ActS showed
strengthened negative correlation and
was superior to ROP stage when stud-
ied together in a multivariable model
against GA, both including all infants
and those with any reported ROP up to
postnatal week 10. However, zone
showed to be superior to modified
ROP-ActS in the association to GA
among infants with any ROP.
Discussion
The current study found that the re-
ordering of the theoretically developed
ROP activity scale (ROP-ActS) would
allow better correspondence to the risk
for developing ROP that needed treat-
ment in this cohort. The modified ROP-
ActS could predict the studied outcome
when applied retrospectively to a large









































































































































Fig. 1. Incidence of ROP treatment for infants ever experiencing ROP Activity Scale (ROP-ActS) scores 1–18. This figure is presenting risk for ROP
treatment for infants ever experiencing a certain score, implying that the same infant might be represented in more than one score.










ActS and ROP zone
OR (95% CI) p-value
Area under
ROC curve
(95% CI) OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Maximum (most severe) value before 10 weeks of PNAa
Original ROP-ActS
(per 1 score increase)
1.52 (1.39–1.67) <0.0001 0.81 (0.76–0.87) 1.39 (1.24–1.56) <0.0001
Modified ROP-ActS
(per 1 score increase)
1.55 (1.41–1.71) <0.0001 0.82 (0.76–0.87) 1.38 (1.23–1.55) <0.0001 1.67 (1.35–2.10) <0.0001 1.42 (1.06–1.91) 0.018
ROP stage(per 1
step increase in severity)
3.22 (2.42–4.27) <0.0001 0.79 (0.73–0.84) 2.94 (1.98–4.37) <0.0001 0.74 (0.36–1.53) 0.42
ROP zone(per 1
step increase in severity)
4.56 (3.23–6.44) <0.0001 0.81 (0.76–0.86) 2.99 (1.98–4.51) <0.0001 1.39 (0.49–3.92) 0.54
BW = birthweight, GA = gestational age, OR = odds ratio, PNA = postnatal age, ROC = receiver operating characteristic, ROP = retinopathy of
prematurity, ROP-ActS = ROP activity scale.
a Number of missing values is n = 11 due to either first visit occurring after 10 weeks of PNA or ROP treatment occurring before 10 weeks of PNA.
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conventionally used both ROP stage
and zone when evaluated statistically.
The modified scale’s sensitivity charac-
teristic, studied through associations to
GA, was shown to be superior com-
pared to ROP stage, but not to ROP
zone.
As improved healthcare worldwide
increases the number of extremely pre-
mature infants at high risk for severe
ROP requiring treatment (Holmstrom
et al., 2019), there is a need to develop
new preventative and safe treatments
for proliferative disease (’’; ’The Mega-
DonnaMega trial’; ’The ROPROP
trial’; Stahl et al., 2019). In order to
have sensitive ROP measures in clinical
trials, a theoretical ROP-ActS taking
into account disease stage, zone and
presence of plus disease was developed
(Smith et al., 2019). The more sensitive
the studied measure, the better is the
ability to discriminate between treat-
ments. This characteristic could be
shown in our study by evaluating
association between GA and the mod-
ified ROP-ActS that was found to be
superior to ROP stage in those analy-
ses. However, ROP zone showed even
better characteristics in a subgroup of
infants with any ROP up to 10 weeks
postnatal age. One explanation for this
finding may be the close relationship
between degree of immaturity and
distance of retinal vascular growth
from the optic disc towards the periph-
ery (Hughes, Yang, & Chan-Ling,
2000). But, zone was not superior to
modified ROP-ActS when studied on
all infants, possibly due to a non-linear
relation between zone and GA. Better
discriminative ability implies higher
statistical power in clinical trials which
might be further increased by improv-
ing the scale’s length of the intervals
between the scores (the scale’s linearity)
to better correspond to the increase in
severity leading to higher risks of the
studied outcome.
Our finding that the modified ROP-
ActS is superior to grading ROP based
on stage or zone alone is based on
prediction analyses of the short-term
outcome evaluating the initial progres-
sion of ROP up to the point of requir-
ing treatment. The scale was not
evaluated with respect to long-term
outcome, although short-term out-
comes are known to predict long-term
outcomes (Hellstrom et al., 2018). The
modified ROP-ActS should be further
validated with regard to long-term
outcome data. The ongoing multicentre
randomized clinical trial
(NCT04004208) administering Eylea
to Type 1 ROP will explore the theo-
retical ROP activity scale as a sec-
ondary outcome (’’).
In our study sample, the majority of
infants (87.1%) had (as expected) no
ROP diagnosed at the first visit, mean-
ing that for most infants the first exam-
inations (which took place according to
the Swedish guidelines) were timely
(Holmstrom et al., 2015). Yet, at the
first examination, 24/535 (4.5%) infants
hadROPdiagnosed in zone II, stage 2 or
3; 10/24 (41.7%) had documented rea-
sons as infant being very sick or difficult/
incomplete examination, and 10/24
(41.7%) were treated for ROP after the
initial examination.
While not studied in detail, there
appears to be less variability of the
postnatal age at first ROP treatment
for the most immature infants, com-
pared to greater variability for infants
with higher GA at birth (data not
shown). This may suggest that in the
most immature infants, immaturity per
se is the dominating risk factor for ROP
treatment while for more mature
infants, external factors may play a
larger role in ROP development. Addi-
tionally, the progression from first ROP
examination to first ROP treatment
appears to be faster for extremely pre-
mature infants, suggesting a more rapid
disease pattern with lower GA at birth.
Although the study cohort is rela-
tively large for infants at high risk for
ROP, only a few cases of very severe
ROP were observed during the study
period. Only two diagnoses of zone I
disease were seen, one with stage 2 and
one with stage 3. Moreover, in the
study group there was no zone 1 with
plus disease, nor any aggressive poste-
rior ROP nor any stage 4a, 4b and 5
disease, resulting in an inability to
evaluate these scores. However, the
nine experts of the original article were
in agreement regarding the severity of
these most aggressive diagnoses so that
validation of these extreme ends of the
spectrum seems less urgent than for the
intermediate scores where there was
more disagreement among the nine
expert graders of the original paper
(Smith et al., 2019).
Table 3. Associations between gestational age and original and modified ROP Activity Scale (ROP-ActS), ROP stage and zone
Univariable linear regression with GA as
dependent variableb
Multivariable linear regression
with GA as dependent variablec
Multivariable linear regression
with GA as dependent variabled
Beta (95% CI) p-value R2 Beta (95% CI) p-value Beta (95% CI) p-value
Maximum (most severe) value before 10 weeks of PNAa
All observations
ROP-ActS 0.42 (0.48; 0.35) <0.0001 0.23
Mod. ROP-ActS 0.42 (0.48; 0.36) <0.0001 0.26 0.55 (0.68; 0.42) <0.0001 0.31 (0.52; 0.10) 0.0042
ROP stage 1.08 (1.29; 0.88) <0.0001 0.17 0.45 (0.03; 0.87) 0.035
ROP zone 1.37 (1.58; 1.17) <0.0001 0.25 0.40 (1.09; 0.29) 0.26
All observations excluding no ROP
ROP-ActS 0.35 (0.45; 0.24) <0.0001 0.20
Mod. ROP-ActS 0.45 (0.55; 0.34) <0.0001 0.29 0.53 (0.64; 0.41) <0.0001 0.14 (0.38; 0.10) 0.25
ROP stage 0.32 (0.85; 0.21) 0.23 0.01 0.75 (0.25; 1.24) 0.0032
ROP zone 2.51 (3.06; 1.96) <0.0001 0.32 1.83 (3.12; 0.53) 0.0059
ROP = retinopathy of prematurity; PNA = postnatal age; GA = gestational age; BW = birthweight; ROP-ActS = ROP activity scale
a Number of missing values is n = 11 due to either first visit occurring after 10 weeks of PNA or ROP treatment occurring before 10 weeks of PNA.
b All analyses are performed using univariable linear regression.
c Multivariable linear regression including mod. ROP-ActS and ROP stage. R2 = 0.26 for all observations, and R2 = 0.33 excluding no ROP.
d Multivariable linear regression including mod. ROP-ActS and ROP zone. R2 = 0.26 for all observations, and R2 = 0.32 excluding no ROP.
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A strength of this study is that a
standardized ROP protocol for data
collection was used at the study site for
each infant and ROP examination
allowing statistical comparison of the
observed ROP-ActS scores. Another
strength is that data entry was com-
plete in almost all cases with reason for
missing data documented. The current
study is representative of the complete
Swedish cohort screened for ROP
(Holmstrom et al., 2019).
As a limitation, the study is based on
data from a single centre in Western
Sweden offering advanced neonatal
care and may not be generalizable to
less developed countries, where timing
of ROP treatment is often not based on
theoretical guidelines, oxygen supple-
mentation may not be monitored and
infants with higher GA at birth are at
risk for ROP (Zepeda-Romero & Gil-
bert, 2015). In the current study, all
infants receiving ROP treatment were
<28 weeks of GA at birth.
The modified ROP activity scale
(ROP-ActS) shows better predictive
ability for ROP treatment than ROP
stage or zone alone. In addition, the
modified scale’s sensitivity characteris-
tic, studied through associations to
GA, was better compared to ROP
stage but not for ROP zone in our
clinical cohort. Further evaluations on
other populations and on long-term
outcomes are recommended, including
the scale’s most important and
requested characteristic that is being
a sensitive score when differentiating
impact of provided preventative ROP
treatments.
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